MedPath

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy (BOOG 2013-07).

Recruiting
Conditions
breast neoplasms
breast cancer
axillary lymph node dissection
mastectomy.
Registration Number
NL-OMON27212
Lead Sponsor
Pink Ribbon, KWF
Brief Summary

.M. van Roozendaal, J.H.W. de Wilt, T. Van Dalen, J.A. van der Hage, L.J.A. Strobbe, L.J. Boersma, S.C. Linn, M.B.I Lobbes, P.M.P. Poortmans, V.C.G Tjan-Heijnen, K.K.B.T. van de Vijver, J. de Vries, A.H. Westenberg, A.G.H. Kessels, M.L. Smidt. The value of completion axillary treatment in sentinel node positive breast cancer patients undergonig a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). BMC Cancer (2015) 15:610 DOI 10.1186/s12885-015-1613-2.

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
878
Inclusion Criteria

1. Female

2. Aged 18 years or older

Exclusion Criteria

1. Clinically node positive pre-operative

2. Sentinel lymph nodes only containing isolated tumour cells (<0.2mm)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Regional recurrence rate after 5- and 10 years of follow-up.<br>
Secondary Outcome Measures
NameTimeMethod
Distant-disease free survival, overall survival, number of delayed axillary lymph node dissections, axillary morbidity rate, quality of life, local recurrence rate, contralateral breast cancer and administration of chest wall radiotherapy after 5- and 10 years of follow-up.
© Copyright 2025. All Rights Reserved by MedPath